Adria Cimino

Key Points Intellia is moving closer and closer to the finish line with two gene-editing candidates. Moderna's future looks bright again with new products on the way. Motley Fool Issues Rare “All In” Buy Alert

Key Points Now is a great moment to invest in technology stocks as a potential artificial intelligence (AI) revolution may lie ahead. It's wise to spread your investment across a basket of players that could win in the AI market over time. Motley Fool Issues Rare “All In” Buy Alert

Key Points AI could solve one of the biggest problems in drug development: the lengthy time it takes to bring a product to market. The AI in healthcare market is set to expand at a compound annual growth rate of nearly 50%. 10 stocks we like better than Moderna

Key Points These two technology stocks could carve out a significant share of the AI market. We're still in the early days of the AI growth story, and these stocks are well positioned to benefit.

Key Points Nvidia stock may have a lot more to gain as it prepares to launch its new Blackwell architecture and best chip yet. Alphabet's and Meta's AI developments could help these tech giants keep advertisers, their biggest revenue source, coming back. 10 stocks we like better than Nvidia

Key Points If history is a guide, the Nasdaq could climb into the double digits this year. Betting on Nasdaq stocks would help you benefit from the momentum -- but you don't have to be a stock-picking expert to do it. Motley Fool Issues Rare “All In” Buy Alert

Key Points The AI market may surpass $1 trillion a few years from now, and companies that invest wisely today could benefit. This particular player is making AI its biggest investment area this year. Motley Fool Issues Rare “All In” Buy Alert

Key Points Nvidia and Intel are both set to launch new AI chips this year, and that could boost their earnings. Another company will benefit from this -- as well as from its own growth. Motley Fool Issues Rare “All In” Buy Alert

Key Points Bull markets favor growth stocks, and that means many biotech players could benefit. Wall Street believes in the potential of these two biotech innovators. Motley Fool Issues Rare “All In” Buy Alert

Key Points Vertex is a leader in cystic fibrosis treatment but also is showing it can succeed in other disease areas. The company recently won approval for a gene-editing treatment for blood disorders. Motley Fool Issues Rare “All In” Buy Alert